These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354 [TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in peripheral T-cell malignancies. Dearden C Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953 [TBL] [Abstract][Full Text] [Related]
7. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699 [TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283 [TBL] [Abstract][Full Text] [Related]
9. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab]. Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804 [TBL] [Abstract][Full Text] [Related]
11. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948 [TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879 [TBL] [Abstract][Full Text] [Related]
14. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Walsh M; Chaudhry A; Jayne D Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469 [TBL] [Abstract][Full Text] [Related]
16. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Dumont FJ Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063 [TBL] [Abstract][Full Text] [Related]
17. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Tuset E; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D Leuk Lymphoma; 2001; 42(6):1379-83. PubMed ID: 11911422 [TBL] [Abstract][Full Text] [Related]
18. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Dyer MJ Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed? Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722 [TBL] [Abstract][Full Text] [Related]